Central nervous system vasculitis

Changed by Henry Knipe, 8 Jan 2015

Updates to Article Attributes

Body was changed:

Central nervous system (CNS) vasculitides represent a heterogeneous group of inflammatory diseases affecting the walls of blood vessels in brain, spinal cord, and the meninges.

Please refer to the article on vasculitis for a general discussion of that entity. 

The aim of this article will be to discuss the primary angiitis of the CNS (PACNS) since the other vasculitides were already discussed in specific articles. 

Terminology

CNS vasculitides are classified as 1-2:

  • primary: when it is confined confined to the CNS with no involvement of other systems - referred as PACNS
  • secondary: it occurs in the context of a systemic inflammatory or infectious process

Please, note that this classification is different from that one used when discussing systemic vasculitides.

Epidemiology

PACNS remains a rare disorder: an estimated average annual incidence rate of 2.4 cases per one million person. It affects patients of all ages, but peaks at around 50 years of age, being maleswith males affected more commonly than females 1.

Secondary causes of CNS vasculitis far exceed in number PACNS 2. Please refer to each specific vasculitis for further details.  

Clinical presentation

Clinical features of PACNS are non-specific. The diagnosis is made based on Calabrese’s criteria 4, including:

  • presence of an acquired otherwise unexplained neurological or psychiatric deficit
  • presence of either classic angiographic or histopathological features of angiitis within the CNS (biopsy remains the standard of reference for its diagnosis diagnosis 3)
  • no evidence of systemic vasculitis or any disorder that could cause or mimic the angiographic or pathological features of the disease

When part of a systemic disorder, the diagnosis may be easier, unless the cerebral symptoms are the first to manifest. Please refer to a specific vasculitis for further details on clinical manifestation. 

Pathology

For almost all forms of vasculitis, including PACNS, the triggering elementfactor is unknown 3

CNS secondary vasculitides:

Radiographic features

Imaging findings for PACNS are usually variable and nonspecific, being the ischemicwith ischemic infarctions the most common lesions, occurring in 53% of cases 5

CT

May show areas of hypoattenuation.

MRI 

Is moreMore specific to show multiple infarctions: usually bilateral, affecting different vascular territories of variable size, and in various stages of healing. 

T2 and FLAIR high intensity lesions in the white matter are also very common in PACNS, but completely nonspecific. 

Meningeal enhancement and intracranial haemorrhages canhaemorrhage can also be seen.

Angiography (DSA)

May showShows focal or multifocal segmental narrowing of both small and medium-sized blood vessels, occlusions are also present. The same findings could be demonstrated in both CTA and MRA. 

Treatment and prognosis

PACNS is managed with high dose steroids and cytotoxic agents 3

History and etymology

PACNS was initially reported in 1959 by Humberto Cravioto and Irwin Feigin 6.

Differential diagnosis

Practical points

Remember that despite of being composed by nonspecific findings, MRI is almost 100% sensitive for PACNS and a normal exam practically excludes this diagnosis 1

  • -<p><strong>Central nervous system (CNS) vasculitides </strong>represent a heterogeneous group of inflammatory diseases affecting the walls of blood vessels in brain, spinal cord, and the meninges.</p><p>Please refer to the article on <a href="/articles/vasculitis">vasculitis</a> for a general discussion of that entity. </p><p>The aim of this article will be discuss the <strong>primary angiitis of the CNS (PACNS) </strong>since the other vasculitides were already discussed in specific articles. </p><h4>Terminology</h4><p>CNS vasculitides are classified as <sup>1-2</sup>:</p><ul>
  • -<li>primary: when it is confined to the CNS with no involvement of other systems - referred as PACNS</li>
  • -<li>secondary: it occurs in the context of a systemic inflammatory or infectious process</li>
  • -</ul><p>Please, note that this classification is different from that one used when discussing systemic vasculitides.</p><h4>Epidemiology</h4><p>PACNS remains a rare disorder: an estimated average annual incidence rate of 2.4 cases per one million person. It affects patients of all ages, but peaks at around 50 years of age, being males affected more commonly than females <sup>1</sup>.</p><p>Secondary causes of CNS vasculitis far exceed in number PACNS <sup>2</sup>. Please refer to each specific vasculitis for further details.  </p><h4>Clinical presentation</h4><p>Clinical features of PACNS are non-specific. The diagnosis is made based on Calabrese’s criteria <sup>4</sup>, including:</p><ul>
  • +<p><strong>Central nervous system (CNS) vasculitides </strong>represent a heterogeneous group of inflammatory diseases affecting the walls of blood vessels in brain, spinal cord, and the meninges.</p><p>Please refer to the article on <a href="/articles/vasculitis">vasculitis</a> for a general discussion of that entity. </p><p>The aim of this article will be to discuss the <strong>primary angiitis of the CNS (PACNS) </strong>since the other vasculitides were already discussed in specific articles. </p><h4>Terminology</h4><p>CNS vasculitides are classified as <sup>1-2</sup>:</p><ul>
  • +<li>primary: confined to the CNS with no involvement of other systems - referred as PACNS</li>
  • +<li>secondary: occurs in the context of a systemic inflammatory or infectious process</li>
  • +</ul><p>Please, note that this classification is different from that one used when discussing systemic vasculitides.</p><h4>Epidemiology</h4><p>PACNS remains a rare disorder: an estimated average annual incidence rate of 2.4 cases per million. It affects patients of all ages, but peaks at around 50 years of age, with males affected more commonly than females <sup>1</sup>.</p><p>Secondary causes of CNS vasculitis far exceed in number PACNS <sup>2</sup>. Please refer to each specific vasculitis for further details.  </p><h4>Clinical presentation</h4><p>Clinical features of PACNS are non-specific. The diagnosis is made based on Calabrese’s criteria <sup>4</sup>, including:</p><ul>
  • -<li>presence of either classic angiographic or histopathological features of angiitis within the CNS (biopsy remains the standard of reference for its diagnosis <sup>3</sup>)</li>
  • +<li>presence of either classic angiographic or histopathological features of angiitis within the CNS (biopsy remains the standard of reference for diagnosis <sup>3</sup>)</li>
  • -</ul><p>When part of a systemic disorder, the diagnosis may be easier, unless the cerebral symptoms are the first to manifest. Please refer to a specific vasculitis for further details on clinical manifestation. </p><h4>Pathology</h4><p>For almost all forms of vasculitis, including PACNS, the triggering element is unknown <sup>3</sup>. </p><p>CNS secondary vasculitides:</p><ul>
  • +</ul><p>When part of a systemic disorder, the diagnosis may be easier, unless the cerebral symptoms are the first to manifest. Please refer to a specific vasculitis for further details on clinical manifestation. </p><h4>Pathology</h4><p>For almost all forms of vasculitis, including PACNS, the triggering factor is unknown <sup>3</sup>. </p><p>CNS secondary vasculitides:</p><ul>
  • -<a title="Takayasu arteritis" href="/articles/takayasu-arteritis">Takayasu arteritis</a> -  uncommon to have CNS involvement</li>
  • -<li><a title="Giant cell arteritis (GCA)" href="/articles/giant-cell-arteritis">giant cell arteritis </a></li>
  • +<a href="/articles/takayasu-arteritis">Takayasu arteritis</a>: uncommon to have CNS involvement</li>
  • +<li><a href="/articles/giant-cell-arteritis">giant cell arteritis </a></li>
  • -<a title="Polyarteritis nodosa (PAN)" href="/articles/polyarteritis-nodosa-1">polyarteritis nodosa </a>(PAN)</li>
  • -<li><a title="Kawasaki disease (KD)" href="/articles/kawasaki-disease">Kawasaki disease </a></li>
  • +<a href="/articles/polyarteritis-nodosa-1">polyarteritis nodosa </a>(PAN)</li>
  • +<li><a href="/articles/kawasaki-disease">Kawasaki disease </a></li>
  • -<li><a title="IgA arteritis" href="/articles/iga-arteritis">IgA arteritis</a></li>
  • +<li><a href="/articles/iga-arteritis">IgA arteritis</a></li>
  • -<a title="Microscopic polyangiitis" href="/articles/microscopic-polyangiitis">microscopic polyangiitis</a> (microscopic polyarteritis)</li>
  • -<li><a title="Granulomatosis with polyangiitis" href="/articles/granulomatosis-with-polyangitis">granulomatosis with polyangiitis</a></li>
  • -<li><a title="Eosinophilic granulomatosis with polyangiitis (EGPA)" href="/articles/eosinophilic-granulomatosis-with-polyangiitis">eosinophilic granulomatosis with polyangiitis</a></li>
  • +<a href="/articles/microscopic-polyangiitis">microscopic polyangiitis</a> (microscopic polyarteritis)</li>
  • +<li><a href="/articles/granulomatosis-with-polyangitis">granulomatosis with polyangiitis</a></li>
  • +<li><a href="/articles/eosinophilic-granulomatosis-with-polyangiitis">eosinophilic granulomatosis with polyangiitis</a></li>
  • -<li><a title="Cogan syndrome" href="/articles/cogan-syndrome">Cogan syndrome</a></li>
  • -<li><a title="CNS manifestations of Behçet disease" href="/articles/cns-manifestations-of-behcet-disease-1">Behçet disease</a></li>
  • +<li><a href="/articles/cogan-syndrome">Cogan syndrome</a></li>
  • +<li><a href="/articles/cns-manifestations-of-behcet-disease-1">Behçet disease</a></li>
  • -<li><a title="Systemic lupus erythematosus" href="/articles/systemic-lupus-erythematosus">SLE</a></li>
  • -<li><a title="Rheumatoid arthritis (RA)" href="/articles/rheumatoid-arthritis">rheumatoid arthritis</a></li>
  • -<li><a title="Sjogren Syndrome" href="/articles/sjogren-syndrome-1">Sjogren syndrome </a></li>
  • -<li><a title="APLA syndrome" href="/articles/antiphospholipid-syndrome">APLA syndrome</a></li>
  • -<li><a title="Scleroderma" href="/articles/scleroderma">scleroderma</a></li>
  • +<li><a href="/articles/systemic-lupus-erythematosus">SLE</a></li>
  • +<li><a href="/articles/rheumatoid-arthritis">rheumatoid arthritis</a></li>
  • +<li><a href="/articles/sjogren-syndrome-1">Sjogren syndrome </a></li>
  • +<li><a href="/articles/antiphospholipid-syndrome">APLA syndrome</a></li>
  • +<li><a href="/articles/scleroderma">scleroderma</a></li>
  • -</ul><h4>Radiographic features</h4><p>Imaging findings for PACNS are usually variable and nonspecific, being the ischemic infarctions the most common lesions, occurring in 53% of cases <sup>5</sup>. </p><h6>CT</h6><p>May show areas of hypoattenuation.</p><h6>MRI </h6><p>Is more specific to show multiple infarctions: usually bilateral, affecting different vascular territories of variable size, and in various stages of healing. </p><p>T2 and FLAIR high intensity lesions in the white matter are also very common in PACNS, but completely nonspecific. </p><p>Meningeal enhancement and intracranial haemorrhages can also be seen.</p><h6>Angiography (DSA)</h6><p>May show focal or multifocal segmental narrowing of both small and medium-sized blood vessels, occlusions are also present. The same findings could be demonstrated in both CTA and MRA. </p><h4>Treatment and prognosis</h4><p>PACNS is managed with high dose steroids and cytotoxic agents <sup>3</sup>. </p><h4>History and etymology</h4><p>PACNS was initially reported in 1959 by <strong>Humberto Cravioto</strong> and <strong>Irwin Feigin </strong><sup>6</sup>.</p><h4>Differential diagnosis</h4><ul>
  • +</ul><h4>Radiographic features</h4><p>Imaging findings for PACNS are usually variable and nonspecific, with <a title="Ischemic infarction" href="/articles/ischaemic-stroke">ischemic infarctions</a> the most common lesions, occurring in 53% of cases <sup>5</sup>. </p><h6>CT</h6><p>May show areas of hypoattenuation.</p><h6>MRI </h6><p>More specific to show multiple infarctions: usually bilateral, affecting different vascular territories of variable size, and in various stages of healing. </p><p>T2 and FLAIR high intensity lesions in the white matter are also very common in PACNS, but completely nonspecific. </p><p><a title="Leptomeningeal enhancement" href="/articles/leptomeningeal-enhancement">Meningeal enhancement</a> and <a title="Intracranial haemorrhage" href="/articles/intracranial-haemorrhage">intracranial haemorrhage</a> can also be seen.</p><h6>Angiography (DSA)</h6><p>Shows focal or multifocal segmental narrowing of both small and medium-sized blood vessels, occlusions are also present. The same findings could be demonstrated in both CTA and MRA. </p><h4>Treatment and prognosis</h4><p>PACNS is managed with high dose steroids and cytotoxic agents <sup>3</sup>. </p><h4>History and etymology</h4><p>PACNS was initially reported in 1959 by <strong>Humberto Cravioto</strong> and <strong>Irwin Feigin </strong><sup>6</sup>.</p><h4>Differential diagnosis</h4><ul>

Tags changed:

  • cases

ADVERTISEMENT: Supporters see fewer/no ads